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Coronary Atherosclerosis in 
Women
Abhishek Ojha and Nishtha Sareen
Abstract
Despite numerous studies focused on women’s cardiac health, deaths from 
cardiovascular disease continue to rise in women. Cardiovascular disease (CVD) 
continues to be the leading cause of death even in women in many areas of the 
world. It has been noted that despite higher frequency of chest pain/angina in 
women compared to men, the incidence of obstructive coronary artery disease 
(CAD) remains lower in the female population compared with men presenting 
with similar symptoms. It is critical to have a deep understanding of these topics 
to ensure a meaningful communication between public, patients, and healthcare 
professionals. One reason to which this discrepancy has been attributed to is that 
chest pain in women is less likely to be secondary to obstructive coronary stenosis 
in comparison to men presenting with similar symptoms. The other issue is that the 
gold standard for coronary atherosclerosis continues to coronary angiography. This 
is a key limitation in cardiovascular atherosclerosis management since endothelial 
dysfunction in addition to a higher risk of atherosclerosis is prevalent in women 
with hypertension, diabetes, and dyslipidemia. In this chapter, we will focus on the 
aspects of coronary atherosclerosis that deserve attention with respect to gender-
specific considerations, particularly with respect to clinical practice.
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1. Introduction
Despite numerous studies focused on women’s cardiac health, deaths from 
cardiovascular disease continue to rise in women. Cardiovascular disease (CVD) 
continues to be the leading cause of death even in women in many areas of the 
world. It has been note that despite higher frequency of chest pain/angina in women 
compared to men, the incidence of obstructive coronary artery disease (CAD) 
remains lower in the female population compared with men presenting with similar 
symptoms [1]. It is critical to have a deep understanding of these topics to ensure a 
meaningful communication between public, patients, and healthcare professionals.
It is important to note that despite all the literature diagnoses, cardiovascular 
illness in women remains underdeveloped. One of the reasons which it has been 
attributed to is that chest pain in women is less likely to be secondary to obstructive 
or flow-limiting coronary stenosis in comparison to men presenting with similar 
symptoms [1]. The other issue is that the gold standard for coronary atherosclerosis 
continues to coronary angiography [1]. This is a key limitation in cardiovascular 
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atherosclerosis management since endothelial dysfunction, in addition to a higher 
risk of atherosclerosis is prevalent in women with hypertension, diabetes, and 
dyslipidemia [2].
Gianturco et al. [3] have also explained the role of systemic inflammation as a 
potential under-recognized player in endothelial dysfunction. Both inflammation 
and immunity seem to be the critical players [3]. The authors have emphasized 
on the need for preventive strategies after detailed understanding of the possible 
underlying pathogenesis [3].
In this chapter, we will focus on the aspects of coronary atherosclerosis that 
deserve attention with respect to gender specific considerations, particularly with 
respect to clinical practice.
2. Pathogenesis
Endothelial dysfunction, inflammation, and atheromatous plaque in women, 
as well as men, is primarily caused as a result of aging, dyslipidemia, hypertension, 
cigarette smoking, and diabetes. These five risk factors mentioned are all well-
known traditional risk factors with well-documented correlation to pathophysiol-
ogy of CAD [4].
2.1 Oral contraceptives and heart disease
Oral contraceptives (OC) have been associated with a higher risk of athero-
sclerosis and venous thrombosis since their introduction in clinical practice [5]. 
The risk for acute heart attack was increased by a factor of 2.5 in those who used 
second-generation contraceptives when compared to third-generation OC (OR1.3) 
on comparison of the different generations of these medications. This suggests a 
lower risk in newer generation OC but the overall findings remain inconclusive. The 
authors, hence, concluded that the recommendation to health care providers should 
include a dedicated screen for traditional cardiovascular risk factors and events 
before prescribing OC [6].
2.2 Pregnancy and heart disease
Pregnancy is associated with elevated atherogenic responses, including insulin 
resistance and dyslipidemia, with consequent manifestation as preeclampsia and 
gestational diabetes. These complications can contribute to higher postpartum risk of 
CVD, with a two-fold increase in CAD and cerebrovascular disease [7]. Preeclampsia 
has been associated with insulin resistance, hypertension, lower high-density 
lipoprotein concentrations, higher plasma levels of triglycerides, high uric acid, and 
high levels of insulin. This is in addition to its recognition as a state of sympathetic 
overactivity and proinflammatory changes [7]. Thus, preeclampsia should be 
carefully evaluated as a potential index manifestation of the metabolic syndrome.
2.3 Parity and heart disease
There is a well-established relationship between number of children, CAD 
risk factors and prevalent CAD in both women and men in the age range of 
60–79 years [8].
The comparison of gender indexes helps delineate whether the association is 
secondary to biological processes or due to lifestyle factors. The results have con-
sistently shown an association of increasing number of children with increasing 
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obesity in both sexes. In women alone, there was suggestion of association between 
number of children and CAD, even after adjustment for obesity and metabolic 
factors [8].
2.4 ACS in women
A detailed review of the Rapid Early Action for Coronary Treatment (REACT) 
study designed by the NHLBI was performed, which tested multistrategy cam-
paigns to reduce patient delay to seek care for ACS symptoms [9]. It was clearly 
shown that reducing the time to treatment was associated with significantly lower 
rates of death and disability caused by AMI [9]. This is critical information for edu-
cation not only of the healthcare providers, but also of patients, individual women 
and the general public. Timely recognition of symptoms of ACS with prompt medi-
cal response to early symptoms can be lifesaving.
The study has, hence, made some direct recommendations. One is patient 
awareness of symptoms in addition to chest pain, pressure, or discomfort. In addi-
tion, the fact is that the symptoms may not be dramatic or sudden. The recognition 
of symptoms by women in the community and the healthcare providers in female 
patients requires further research. This research should focus on the prodromal 
syndromes with dedicated dissemination of public messages and information aimed 
at healthcare providers. Lastly, the NHLBI document diligently encourages better 
understanding of all pathophysiological basis of ACS in women with the intention 
to optimize treatment recommendations.
2.5 Endothelial dysfunction
Endothelium interacts with nearly each and every system of the human body, with 
definite implication in end organ diseases of systems including neurologic, renal, 
hepatic, vascular, dermatologic, immunologic, and cardiac [10]. Additionally, the 
endothelium regulates vascular tone, maintaining careful balance between vasocon-
striction and vasodilation with the intention to provide adequate perfusion pressure to 
target organs. Additional functions include regulation of angiogenesis, wound heal-
ing, smooth muscle cell proliferation, fibrosis, and inflammation [10]. Interestingly, 
the factors that adversely affect the endothelium are also the common cardiovascular 
risk factors such as tobacco use, obesity, age, hypertension, hyperlipidemia, physical 
inactivity, and poor dietary habits [10].
3. Management strategies of atherosclerosis in women
It has been shown in studies that in female patients with coronary artery disease, 
persistent impairment of endothelial vasomotor function despite optimized therapy 
to reduce risk factors can adversely affect clinical outcomes [11].
The following, however, should be aggressively managed to combat atheroscle-
rotic disease in female patients:
1. Life style modifications (diet, exercise, smoking, weight reduction)
Adherence with healthy eating habits, regular exercising and weight reduction 
are all important determinants of atherosclerosis and should be recommended in 
both genders [12]. Smoking cessation is critical and dedicated time should be spent 
with patients to generate that awareness [12].
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2. Receptor and enzyme pathways (beta-blockers, ET, ACE-I, ARB)
Just as the traditional risk factors play a critical role in the pathogenesis of 
atherosclerotic CAD in females, the routine therapies should be considered in this 
patient population [13].
Most studies have found the benefit of statins in ameliorating and even eliminat-
ing endothelial dysfunction [13]. These medications are well known mainstay in 
decreasing CVD risk in most patients secondary to their lipid-lowering and anti-
inflammatory mechanism [13]. Addition of ACE-inhibition to statin therapy has 
been shown to improve endothelial-dependent relaxation in the coronary vascula-
ture through NO-dependent mechanism [14, 15].
3. NO pathway (L-arginine, PDE-I)
Both intravenous and intracoronary administration of L-arginine, the 
physiologic precursor for NO, has been shown to acutely improve endothelium-
dependent, but not endothelium-independent, vasodilation in participants with 
hypercholesterolemia or CAD [16]. The longer-term effects of oral L-arginine have 
additionally been evaluated. Among patients who have underlying heart failure, 
oral L-arginine improved endothelial function, arterial compliance, and functional 
status [17].
The other agent is Nicorandil, which is a potent antianginal, however, unavail-
able in the US. It has dual nitrate and potassium-ATP channel agonist properties 
and increases the formation of cyclic GMP. This agent has been shown to improve 
endothelial function in patients without prior CAD at 1 year follow up with con-
comitant documented reductions in inflammatory markers [18].
4. Channel pathways (Ca, K)
Nifedipine has been shown to have antioxidant effects with additional effect 
on endothelial nitric oxide synthase expression. In a study including 454 patients 
undergoing percutaneous coronary intervention, endothelium dependent vaso-
dilatation was evaluated with intracoronary acetylcholine following 6 months of 
therapy with nifedipine. There was well documented improvement in endothelial 
function, however, no plaque regression [19].
Ranolazine is a sodium channel inhibitor used in patients who have  refractory 
angina. It has been shown to improve symptoms of microvascular angina, 
 however there was no clear change seen in microvascular function with the use 
of  ranolazine [20].
4. Conclusion
In summary, atherosclerosis in females is a complex process. There is an integral 
role of endothelial dysfunction. In order to close the gaps in care of cardiac disease 
in women, the steps must include timely recognition of the symptoms of cardiac 
disease with the effective management. Treatment strategies are diverse with decent 
evidence base. Larger studies dedicated to address atherosclerosis in women are 
urgently required.
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